Sheila López‐Cobo

Author

Sheila López‐Cobo

Centro Nacional de Biotecnología ORCID

Also Known As

S Lopez-Cobo, S. Lopez-Cobo, Sheila Lopez-Cobo, Sheila LÃ³pez-Cobo, Sheila López-Cobo, Sheila López‐Cobo

Publications

725

Citations

H-Index

Concepts

All Affiliations

Centro Nacional de Biotecnología Consejo Superior de Investigaciones Científicas Universidad Autónoma de Madrid Hospital Universitario Infanta Sofía Deutschen Konsortium für Translationale Krebsforschung

About

Sheila López‐Cobo is an author at Centro Nacional de Biotecnología specializing in cell signaling, medicine, and cell biology.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	3	3	138
2	Cell Biology	3	3	138
3	Immunology	3	3	138
4	Cell Signaling	3	3	138
5	Pathology	1	1	44

Sheila López‐Cobo

Publications

675

Citations

H-Index

Page 1

	Year	Citations
Development of a rapid lateral flow immunoassay test for detection of exosomes previously enriched from cell culture medium and body fluids Myriam Oliveira-Rodríguez, Sheila López‐Cobo, Hugh T. Reyburn, Journal of Extracellular Vesicles	2016	162
Immunoassays for scarce tumour-antigens in exosomes: detection of the human NKG2D-Ligand, MICA, in tetraspanin-containing nanovesicles from melanoma Sheila López‐Cobo, Carmen Campos‐Silva, Amanda Moyano, Journal of Nanobiotechnology	2018	81
Natural killer (NK) cell-derived extracellular-vesicle shuttled microRNAs control T cell responses Sara G. Dosil, Sheila López‐Cobo, Ana Rodríguez‐Galán, eLife	2022	78
A GPI anchor explains the unique biological features of the common NKG2D-ligand allele MICA*008 Omodele Ashiru, Sheila López‐Cobo, Lola Fernández‐Messina, Biochemical Journal ImmunologyImmune RegulationImmunodominanceHuman MicaImmunologic Mechanism	2013	76
Impaired NK cell recognition of vemurafenib-treated melanoma cells is overcome by simultaneous application of histone deacetylase inhibitors Sheila López‐Cobo, Natalia Pieper, Carmen Campos‐Silva, OncoImmunology	2017	59
<i>SUV39H1</i> Ablation Enhances Long-term CAR T Function in Solid Tumors Sheila López‐Cobo, Jaime R. Fuentealba, Paul Gueguen, Cancer Discovery	2023	47
NKG2D is a Key Receptor for Recognition of Bladder Cancer Cells by IL-2-Activated NK Cells and BCG Promotes NK Cell Activation Eva M. García‐Cuesta, Sheila López‐Cobo, Mario Álvarez‐Maestro, Frontiers in Immunology Cancer ImmunosurveillanceIl-2-activated Nk CellsMedicineImmunologyImmunoediting	2015	44
Characterization of a human anti-tumoral NK cell population expanded after BCG treatment of leukocytes Eva M. García‐Cuesta, Gloria Esteso, Omodele Ashiru, OncoImmunology	2017	39
BCG Therapy of Bladder Cancer Stimulates a Prolonged Release of the Chemoattractant CXCL10 (IP10) in Patient Urine Omodele Ashiru, Gloria Esteso, Eva M. García‐Cuesta, Cancers	2019	22
Transfer of the human <scp>NKG</scp>2D ligands <scp>UL</scp>16 binding proteins (ULBP) 1–3 is related to lytic granule release and leads to ligand retransfer and killing of <scp>ULBP</scp>‐recipient natural killer cells Sheila López‐Cobo, Gema Romera‐Cárdenas, Eva M. García‐Cuesta, Immunology	2015	19

Page 1